Novartis to acquire inflammasome-focused IFM Tre
Tuesday, May 28, 2019 - 21:10
in Mathematics & Economics
The big company is bolstering its portfolio with three NLRP3 antagonists
The big company is bolstering its portfolio with three NLRP3 antagonists